← Browse by Condition
Medical Condition

age related macular degeneration

Total Trials
9
Recruiting Now
9
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 1, Phase 2
NCT06924021
Recruiting

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

Enrollment
1,000 pts
Location
United States, Argen...
Sponsor
University of Wisconsin, Madis...
View Trial →
NCT06351670
Recruiting

Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression

Enrollment
500 pts
Location
Austria, France, Slo...
Sponsor
Medical University of Vienna
View Trial →
NCT06572553 Phase 2, Phase 3
Recruiting

Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients

Enrollment
30 pts
Location
China
Sponsor
Second Affiliated Hospital, Sc...
View Trial →
NCT06961370 Phase 1
Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Enrollment
132 pts
Location
United States
Sponsor
Hoffmann-La Roche
View Trial →
NCT07002372
Recruiting

Effect of Video Viewing on Intravitreal Injection Experience

Enrollment
182 pts
Location
China
Sponsor
Second Affiliated Hospital, Sc...
View Trial →
NCT03011541
Recruiting

Stem Cell Ophthalmology Treatment Study II

Enrollment
500 pts
Location
United States, Austr...
Sponsor
MD Stem Cells
View Trial →
NCT06619405
Recruiting

AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance

Enrollment
100 pts
Location
United States
Sponsor
Duke University
View Trial →
NCT07160179 Phase 1, Phase 2
Recruiting

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Enrollment
66 pts
Location
United States
Sponsor
AbbVie
View Trial →
NCT06662162
Recruiting

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Enrollment
100 pts
Location
Australia, New Zeala...
Sponsor
i-Lumen Scientific AUS PTY LTD
View Trial →